A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 38/04 (2006.01) A61K 38/05 (2006.01) A61K 38/06 (2006.01) A61K 38/07 (2006.01) A61K 38/08 (2006.01) A61K 38/09 (2006.01) A61K 38/10 (2006.01) A61K 38/16 (2006.01) A61K 38/17 (2006.01) C07K 5/04 (2006.01) C07K 5/06 (2006.01) C07K 5/068 (2006.01) C07K 5/08 (2006.01) C07K 5/097 (2006.01) C07K 5/10 (2006.01) C07K 5/103 (2006.01) C07K 7/04 (2006.01) C07K 7/06 (2006.01) C07K 14/46 (2006.01) G01N 33/566 (2006.01) G01N 33/567 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2421786
Obtustatin is a novel, RGD-independent short disintegrin that potently and selectively inhibits the binding of .alpha.1.beta.1 integrin to its adhesive ligand. Obtustatin, and fragments, derivatives, homologs and analogs of obtustatin may be used to treat diseases and modulate biological conditions associated with .alpha.1.beta.1 integrin.
L'invention concerne l'obtustatine, une disintégrine courte indéprendante de la séquence RGD (arginine-glycine-acide aspartique), qui a une action inhibitrice puissante et sélective sur la liaison de l'intégrine .alpha.1.beta.1 avec son ligand d'adhésion. On peut utiliser l'obtustatine, y compris ses fragments, dérives, homologues et analogues, pour le traitement des maladies et pour moduler les états biologiques associés à l'intégrine .alpha.1.beta.1.
Mccarthy Tetrault Llp
Temple University - Of The Commonwealth System Of Higher Educati
LandOfFree
Compounds and methods for inhibiting alpha-1 beta-1 integrins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods for inhibiting alpha-1 beta-1 integrins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for inhibiting alpha-1 beta-1 integrins will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1444882